ILMN

95.91

3.13% 2.91

Dopo l'orario di chiusura: 96.50 0.59 +0.62%

Illumina Inc (ILMN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ILMN Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$93.00

Aprire:

$94.05

Volume 24 ore:

2.16M

Relative Volume:

1.24

Capitalizzazione di mercato:

$14.74B

Reddito:

$4.28B

Utile/perdita netta:

$1.26B

Rapporto P/E:

12.14

EPS:

7.9

Flusso di cassa netto:

$943.00M

1 W Prestazione:

-0.56%

1M Prestazione:

-5.49%

6M Prestazione:

+30.44%

1 anno Prestazione:

-33.34%

Intervallo 1D:

$93.50

$98.70

Intervallo di 1 settimana:

$88.00

$98.70

Portata 52W:

$68.70

$156.66

Illumina Inc Stock (ILMN) Company Profile

Nome

Illumina Inc

Settore

Healthcare (1140)

Industria

Diagnostics & Research (53)

Telefono

(858) 202-4500

Indirizzo

5200 ILLUMINA WAY, SAN DIEGO, CA

Dipendente

8,970

Cinguettio

@illumina

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

ILMN's Discussions on Twitter

Confronta ILMN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ILMN Illumina Inc	95.91	13.99B	4.28B	1.26B	943.00M	7.90
TMO Thermo Fisher Scientific Inc	536.78	198.56B	43.21B	6.58B	6.17B	17.28
DHR Danaher Corp	210.92	147.61B	24.01B	3.41B	4.86B	4.7082
IDXX Idexx Laboratories Inc	637.34	50.96B	4.04B	985.66M	774.34M	12.01
A Agilent Technologies Inc	141.10	39.13B	6.79B	1.22B	1.09B	4.2644
IQV Iqvia Holdings Inc	205.75	34.81B	15.70B	1.24B	2.01B	6.9036

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-12	Downgrade	Daiwa Securities	Outperform → Neutral
2025-07-11	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2025-03-04	Reiterato	Citigroup	Neutral
2025-02-28	Downgrade	HSBC Securities	Buy → Hold
2025-02-10	Downgrade	Barclays	Equal Weight → Underweight
2025-02-07	Downgrade	TD Cowen	Buy → Hold
2024-12-11	Downgrade	Citigroup	Buy → Neutral
2024-11-12	Ripresa	Morgan Stanley	Equal-Weight
2024-10-17	Aggiornamento	HSBC Securities	Hold → Buy
2024-08-28	Aggiornamento	Argus	Hold → Buy
2024-08-16	Aggiornamento	Daiwa Securities	Neutral → Buy
2024-08-14	Aggiornamento	Barclays	Underweight → Equal Weight
2024-08-14	Aggiornamento	TD Cowen	Hold → Buy
2024-07-10	Aggiornamento	Citigroup	Neutral → Buy
2024-06-03	Ripresa	Jefferies	Hold
2024-01-16	Downgrade	HSBC Securities	Buy → Hold
2024-01-04	Downgrade	TD Cowen	Outperform → Market Perform
2023-12-18	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2023-12-15	Aggiornamento	Bernstein	Underperform → Mkt Perform
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-14	Iniziato	Stephens	Overweight
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-12-12	Downgrade	BofA Securities	Neutral → Underperform
2023-12-11	Aggiornamento	Citigroup	Sell → Neutral
2023-11-10	Downgrade	Canaccord Genuity	Buy → Hold
2023-09-28	Iniziato	Bernstein	Underperform
2023-07-05	Ripresa	JP Morgan	Neutral
2023-01-25	Downgrade	Argus	Buy → Hold
2023-01-05	Iniziato	Scotiabank	Sector Perform
2022-12-12	Downgrade	Citigroup	Neutral → Sell
2022-12-07	Iniziato	RBC Capital Mkts	Outperform
2022-10-04	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2022-09-28	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-25	Iniziato	Credit Suisse	Neutral
2022-07-13	Downgrade	Barclays	Equal Weight → Underweight
2022-01-18	Aggiornamento	Stifel	Hold → Buy
2022-01-11	Aggiornamento	Barclays	Underweight → Equal Weight
2022-01-07	Aggiornamento	BofA Securities	Underperform → Neutral
2022-01-06	Ripresa	Morgan Stanley	Equal-Weight
2022-01-06	Ripresa	Piper Sandler	Overweight
2021-10-15	Ripresa	Cowen	Outperform
2021-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-06-01	Aggiornamento	Evercore ISI	Underperform → In-line
2021-03-31	Downgrade	Atlantic Equities	Overweight → Neutral
2021-03-31	Aggiornamento	Canaccord Genuity	Hold → Buy
2021-03-03	Iniziato	Barclays	Underweight
2020-12-22	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-12-17	Aggiornamento	BTIG Research	Neutral → Buy
2020-10-13	Downgrade	Guggenheim	Buy → Neutral
2020-09-30	Iniziato	Atlantic Equities	Overweight
2020-09-29	Downgrade	Wolfe Research	Outperform → Peer Perform
2020-09-22	Downgrade	Stifel	Buy → Hold
2020-09-22	Downgrade	UBS	Buy → Neutral
2020-09-21	Aggiornamento	Guggenheim	Neutral → Buy
2020-09-21	Downgrade	JP Morgan	Overweight → Neutral
2020-09-09	Iniziato	Morgan Stanley	Equal-Weight
2020-08-07	Downgrade	Evercore ISI	In-line → Underperform
2020-08-07	Downgrade	Piper Sandler	Overweight → Neutral
2020-07-07	Downgrade	Guggenheim	Buy → Neutral
2020-04-24	Downgrade	Citigroup	Buy → Neutral
2020-04-21	Downgrade	Robert W. Baird	Outperform → Neutral
2020-01-08	Iniziato	Wells Fargo	Underweight
2020-01-07	Iniziato	Citigroup	Buy
2020-01-02	Downgrade	Evercore ISI	Outperform → In-line
2019-11-15	Iniziato	Stifel	Buy
2019-10-25	Iniziato	Guggenheim	Buy

Mostra tutto

Illumina Inc Borsa (ILMN) Ultime notizie

12:43 PM

Why Illumina Inc. stock is in analyst buy zoneCEO Change & Weekly Watchlist for Hot Stocks - newser.com

12:43 PM

07:34 AM

Guggenheim maintains Illumina stock Buy rating following Roche’s AXELIOS pricing - Investing.com

07:34 AM

Oct 15, 2025

How Illumina Inc. (ILMN) Affects Rotational Strategy Timing - news.stocktradersdaily.com

Oct 15, 2025

Illumina's constellation tech a star in Genedx pilot - BioWorld MedTech

Oct 15, 2025

Long term hold vs stop loss in Illumina Inc.July 2025 Summary & Technical Pattern Based Buy Signals - newser.com

Oct 15, 2025

Fast and reliable solutions for oncology workflows - Illumina

Oct 15, 2025

Illumina Inc. stock momentum explainedPortfolio Risk Report & Reliable Entry Point Trade Alerts - newser.com

Oct 15, 2025

Sentiment analysis tools applied to Illumina Inc.Global Markets & Low Risk High Reward Trade Ideas - newser.com

Oct 15, 2025

Illumina, Inc. Fuels Multiomic Discovery with Launch of 5-Base Solution, Unveils Simpling Gen Genome and Epigenomic Insights - MarketScreener

Oct 15, 2025

Will Illumina Inc. stock remain a Wall Street favorite2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com

Oct 15, 2025

Illumina’s constellation tech shows promise in GeneDx rare disease study - Investing.com

Oct 15, 2025

Illumina Inc. Stock Slides 4.2%, Underperforms Peers - 富途牛牛

Oct 15, 2025

Illumina launches 5-base solution for dual genomic analysis - Investing.com India

Oct 15, 2025

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot - MarketScreener

Oct 15, 2025

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights - PR Newswire

Oct 15, 2025

Will Illumina Inc. stock benefit from commodity prices2025 Momentum Check & Real-Time Chart Pattern Alerts - newser.com

Oct 15, 2025

What data driven models say about Illumina Inc.’s futureJuly 2025 Pullbacks & Capital Protection Trading Alerts - newser.com

Oct 15, 2025

Oct 14, 2025

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - MarketScreener

Oct 14, 2025

Genomic Cancer Testing Market Trends, Investment - openPR.com

Oct 14, 2025

Is Illumina Inc. stock safe for conservative investorsWeekly Risk Summary & Reliable Intraday Trade Alerts - newser.com

Oct 14, 2025

Oct 13, 2025

What consensus target says about Illumina Inc. (ILU) stockLong Setup & Accurate Technical Buy Alerts - newser.com

Oct 13, 2025

Microfluidic Market to See Booming Growth 2025-2032 | Agilent Technologies, Inc., Illumina, Inc. - openPR.com

Oct 13, 2025

Aberdeen Group plc Trims Holdings in Illumina, Inc. $ILMN - MarketBeat

Oct 13, 2025